Views: 0 Author: Site Editor Publish Time: 2026-08-28 Origin: Site
A decades‑long large‑scale study
Conducted jointly by the American Cancer Society (ACS) and the Rollins School of Public Health at Emory University, this long‑term research followed 1,357 participants who were cancer‑free at baseline.
All participants were in good health when their blood was drawn. Researchers collected their plasma samples and measured more than 1,100 small‑molecule metabolites in the blood. Meanwhile, using air‑monitoring data tied to residential addresses, they estimated each individual’s long‑term exposure to six major air pollutants: PM2.5, PM10, nitrogen dioxide, ozone, carbon monoxide and sulfur dioxide.
The team carried out follow‑up assessments over several years.
Among the participants who later developed lung cancer (671 cases), molecular signatures left by air pollution could already be detected in blood samples taken 2‑7 years before formal diagnosis.
The study identified eight blood metabolites correlated with both air‑pollution exposure and elevated lung‑cancer risk. Four of these metabolites showed statistically significant mediating effects linking pollutants to lung‑cancer development.
These metabolites are involved in four core human physiological pathways:
Chronic inflammation
Oxidative stress (free‑radical damage to cells)
Hepatic detoxification function
Energy metabolism
In other words, long‑term inhalation of polluted air quietly drives dysregulation across these four biological systems — and these molecular changes emerge far earlier than coughs, pulmonary nodules, or shadows visible on CT scans.
Notably, these molecular‑level alterations were most pronounced among never‑smokers.
In reality, more than half of global lung‑cancer cases occur in people who have never smoked or do not meet current lung‑cancer screening criteria. They may believe they face “no lung‑cancer risk”, yet metabolic signals in their blood tell a different story.
It demonstrates that harm from air pollution is a silent, cumulative, molecular‑scale process. By the time physical symptoms appear, damage may have persisted for many years.
Crucially: indoor air is not inherently safer than outdoor air. Cooking fumes, emissions from furniture, dust mites and mould in enclosed spaces, and pet dander constitute ongoing sources of exposure.
Most people spend over 80 % of their time indoors. The air quality you can actively manage is the environment inside your four walls.
Guided by this understanding, Kangbeijing has launched the KJ‑A7 Plasma Air Disinfection Purifier.
Designed for indoor spaces where people stay for extended periods — bedrooms, children’s rooms, studies and offices — it abandons bulky tower‑style hardware. Its compact form supports wall‑mount installation, or placement on desktops and cabinet tops: unobtrusive and space‑saving, while running quietly 24‑7.
DBD Plasma Technology: Actively inactivates airborne harmful microorganisms. Rather than relying solely on passive filtration, it reduces airborne viable bacteria and viral loads at the source.
Composite Filter + High‑Air‑Volume Circulation: Captures particulate matter, hair and dust to accelerate indoor air renewal.
Zero‑Ozone Design: Generates no respiratory‑irritating by‑products. Safe for continuous operation in rooms for the elderly, children, and expectant users.
Disinfection‑Product Registration: Filed under China’s national disinfection‑product regulatory system, with dual assurances of quality and regulatory compliance.
This is not a medical device, nor a universal remedy.
Please maintain rational expectations: the KJ‑A7 is an air‑purification and disinfection device, serving as a supplementary measure for indoor air‑quality management. It works to minimise sustained exposure to airborne pollutants within your living environment. It cannot replace professional medical interventions, and it does not constitute disease prevention or treatment.
Health cannot be guaranteed by any single product. Still, when it comes to “what air you breathe”, you can make a deliberate choice.